Wave Life Sciences, Inc. (WVE) Stock Price & Analysis
Wave Life Sciences, Inc. (WVE) rose 3.40% to USD 4.86 as of September 8, 2026 at 10:49 UTC, according to Nexqual real-time market data.
WVE last closed at USD 4.7; the session ranged USD 4.65–4.89 on volume of 3,030,266 shares. Market capitalization is $957.65M, with a 52-week range of USD 4.65–21.73 (NGM). Source: Nexqual, September 8, 2026 at 10:49 UTC.
Key Statistics (as of September 8, 2026 at 10:49 UTC)
| Price | USD 4.86 |
|---|---|
| Change | ▲ 3.40% (up) |
| Previous Close | USD 4.7 |
| Open | USD 4.75 |
| Day Range | USD 4.65 – 4.89 |
| 52-Week Range | USD 4.65 – 21.73 |
| Volume | 3,030,266 shares |
| Market Cap | $957.65M |
| Exchange | NGM |
Technical Analysis (WVE)
Nexqual's technical model rates WVE "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 10:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.29 (neutral) |
| vs SMA50 | Below (USD 5.63) |
| MACD | -0.23 (negative) |
Analyst Ratings (WVE)
Wall Street analysts rate WVE "Strong Buy" based on 16 analysts, with a mean price target of USD 19.06 (range USD 12–42), per Nexqual as of September 8, 2026 at 10:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 19.06 |
| High Target | USD 42 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 16 / 0 / 0 |
Earnings (WVE)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.32 |
| Revenue Estimate | $4.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.34 vs est -0.3 ▼ miss |
| 2026-03-31 | USD -0.13 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.3 vs est -0.26 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.3 ▼ miss |
Source: Nexqual, September 8, 2026 at 10:49 UTC.
Financials & Fundamentals (WVE)
| Total Revenue | $65.37M |
|---|---|
| Revenue Growth (YoY) | -73.90% |
| Gross Margin | -202.00% |
| Operating Margin | -3248.33% |
| Profit Margin | +0.00% |
| ROE | -67.42% |
| Debt / Equity | 9.61 |
| Current Ratio | 9.99 |
| Total Cash | $490.60M |
| Total Debt | $43.59M |
| Free Cash Flow | $-128.78M |
Source: Nexqual, September 8, 2026 at 10:49 UTC.
Financial Health Score (WVE)
Nexqual rates Wave Life Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 10:49 UTC.
| Growth | Critical — Revenue -61% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $491M cash vs $44M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$129M, burning cash |
| Efficiency | Critical — ROE -67%, ROA -33.6% |
Ownership (WVE)
| Insider Ownership | +15.50% |
|---|---|
| Institutional Ownership | +85.35% |
| Shares Outstanding | 197.05M |
| Float | 94.57M |
| Short % of Float | +10.14% |
Source: Nexqual, September 8, 2026 at 10:49 UTC.
Leadership (WVE)
Wave Life Sciences, Inc. is led by Paul B. Bolno (age 51), President, CEO & Director, per Nexqual as of September 8, 2026 at 10:49 UTC.
| President, CEO & Director | Paul B. Bolno (age 51) |
|---|---|
| Founder & Director | Gregory L. Verdine (age 66) |
| CFO & Principal Accounting Officer | Kyle B. Moran (age 54) |
| Chief Technology Officer | Chandra Vargeese (age 64) |
| Chief Scientific Officer | Erik Ingelsson |
Major Backers & Investors (WVE)
Notable institutional backers of Wave Life Sciences, Inc. include PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund, Fidelity, T. Rowe Price, according to Nexqual as of September 8, 2026 at 10:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 2.09% |
| Fidelity | 1.6% |
| T. Rowe Price | 0.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.7% |
| Vanguard Group | 0.89% |
| State Street | 0.59% |
Source: Nexqual, September 8, 2026 at 10:49 UTC.
From Wave Life Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our HD Program WVE-003 is our stereopure allele-selective oligonucleotide that incorporates our proprietary PN chemistry and is designed to selectively target rs362273, a variant of the single nucleotide polymorphism ("SNP"), "mHTT SNP3", associated with the disease-causing mHTT mRNA transcript within the HTT gene (Iwamoto et al., MTNA).
- PRISM: Our proprietary discovery and drug development platform Our PRISM platform demonstrates the powerful convergence of best-in-class chemistry with human genetics.
- Our Proprietary Chemistry Backbone Stereochemistry In our foundational Nature Biotechnology paper (Iwamoto N, et al.
- Nature Biotechnol. 2017;35(9):845-851), we described our studies using our proprietary chemistry to design and synthesize stereopure oligonucleotides and oligonucleotide mixtures based on mipomersen.
Partnerships
- With respect to the $50.0 million equity investment referred to above, simultaneously with our entry into the GSK Collaboration Agreement, we entered into a share purchase agreement with Glaxo Group Limited ("GGL"), an affiliate of GSK, pursuant to which we agreed to sell to GGL 10,683,761 of our ordinary shares at a purchase price of $4.68 per share, for an aggregate purchase price of approximately $50.0 million (the "GSK Equity Investment").
- Treatments are available to help deal with intestinal bleeding, fluid in the abdomen, nutritional issues, and other complications from scarring of the liver, but ultimately many patients will progress towards requiring a liver transplant.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRRK | Scholar Rock Holding Corporatio | USD 55.33 | ▼ 1.37% |
| VYGR | Voyager Therapeutics, Inc. | USD 3.51 | ▼ 0.85% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.71 | ▼ 0.27% |
| SLDB | Solid Biosciences Inc. | USD 10.25 | ▼ 0.34% |
| RGNX | REGENXBIO Inc. | USD 8.94 | ▼ 6.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:49 UTC. This page is informational and not investment advice.